

ONCOLOGY

Lecture Notes



Mark Bower
Jonathan Waxman

3rd Edition

LN



WILEY Blackwell

This title is also available as an e-book.

Formore details, please see

www.wiley.com/buy/9781118842096

or scan this QR code:



Oncology

Lecture Notes

Mark Bower

Professor of Oncology
Chelsea and Westminster Hospital and
Imperial College School of Medicine
London, UK

Jonathan Waxman

Professor of Oncology
Hammersmith Hospital
Imperial College School of Medicine
London, UK

Third Edition

WILEY Blackwell

This edition first published 2015 © 2015 by John Wiley & Sons, Ltd
Previous editions: 2006, 2010 © Mark Bower and Jonathan Waxman

Registered office: John Wiley & Sons, Ltd, The Atrium, Southern Gate,
Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, servicemarks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or

disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Bower, Mark, author.

Lecture notes. Oncology/Mark Bower, Jonathan Waxman-Third edition.

p.; cm.

Oncology

Oncology lecture notes

Includes bibliographical references and index.

ISBN 978-1-118-84209-6 (pbk.)

I. Waxman, Jonathan, author. II. Title. III. Title: Oncology. IV. Title: Oncology lecture notes.

[DNLM: 1. Neoplasms. QZ 200]

RC254.5

616.99'4-dc23

2015004427

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image: Stockphoto@royalsrockphoto

Contents

[Preface](#)

[About the companion website](#)

[Part 1 Introduction to oncology](#)

[1 What is cancer?](#)

[Epidemiological perspective](#)

[How to read a histology report](#)

[A histopathological definition of cancer: is it malignant or benign?](#)

[Cancer epidemiology](#)

[Cancer charities](#)

[2 The scientific basis of cancer](#)

[The hallmarks of cancer](#)

[How to acquire the six capabilities \(enabling hallmarks\)](#)

[Additional capabilities of cancers \(emerging hallmarks\)](#)

[Genome instability](#)

[Genetic causes of cancer](#)

[Environmental causes of cancer](#)

[Worldwide contributions to cancer](#)

[3 The principles of cancer treatment](#)

[Appropriate care](#)

[Cancer staging](#)

[Performance status](#)

[Prognosis: it is not cancer, is it doc?](#)

[Surgical oncology](#)

[Radiotherapy](#)
[Chemotherapy](#)
[Endocrine therapy](#)
[Immunological therapy](#)
[Targeted therapies](#)
[Clinical trials](#)
[Palliative care](#)

[4 Cancer and people](#)

[Social and psychological aspects of cancer](#)
[Unconventional treatments](#)
[Ethics](#)
[Sociology of oncology](#)

[Part 2 Types of cancer](#)

[5 Breast cancer](#)

[Epidemiology](#)
[Presentation and screening](#)
[Diagnosis](#)
[Staging and grading](#)
[Treatment](#)
[Carcinoma *in situ*](#)
[Paget's disease of the nipple](#)
[Male breast cancer](#)

[6 Central nervous system cancers](#)

[Epidemiology](#)
[Aetiology](#)
[Pathology](#)
[Presentation](#)
[Investigation and staging](#)

Treatment

Prognosis

7 Oesophageal cancer

Epidemiology and pathogenesis

Prevention

Presentation

Staging and grading

Treatment

Prognosis

8 Gastric cancer

Epidemiology and pathogenesis

Presentation

Staging and pathology

Treatment

Survival

9 Hepatobiliary cancer

Epidemiology

Pathogenesis

Prevention

Presentation

Staging and grading

Treatment

Prognosis

10 Pancreatic cancer

Epidemiology

Pathogenesis

Presentation

Staging and grading

Treatment

Prognosis

Pancreatic endocrine tumours

11 Colorectal cancer

Epidemiology

Pathogenesis

Presentation

Diagnosis

Staging and grading

Treatment

Management of metastatic disease

Screening

12 Kidney cancer

Epidemiology

Pathogenesis

Presentation

Outpatient diagnosis

Staging and grading

Treatment

Anti-angiogenic therapy

Targeted therapy

Prognosis

13 Bladder cancer

Epidemiology

Pathogenesis

Presentation

Staging and grading

Treatment

Prognosis

14 Prostate cancer

Epidemiology

Pathogenesis

Presentation

Staging and grading

Treatment

Prognosis

Screening

15 Testis cancer

Epidemiology

Pathogenesis

Presentation

Staging and grading

Treatment

Prognosis

16 Gestational trophoblastic disease

Epidemiology

Pathogenesis

Presentation

Treatment

Prognosis

17 Cervical cancer

Epidemiology

Pathogenesis

Screening

Prevention (vaccination)

Presentation

Outpatient diagnosis

Staging and grading

Treatment

Cervical intraepithelial neoplasia

Prognosis

Terminal care

18 Endometrial cancer

Epidemiology

Pathogenesis

Presentation

Treatment and prognosis

19 Ovarian cancer

Epidemiology

Pathogenesis

Screening

Presentation

Staging and grading

Treatment

Prognosis

20 Head and neck cancers

Epidemiology

Pathogenesis

Clinical presentation

Treatment

Prognosis

Salivary gland tumours

21 Thyroid cancer

Epidemiology

[Pathogenesis](#)

[Presentation](#)

[Investigations](#)

[Treatment](#)

[Prognosis](#)

[22 Adrenal cancers](#)

[Epidemiology of adrenal cortical cancers](#)

[Presentation of adrenal cortical cancers](#)

[Investigations of adrenal cortical cancers](#)

[Initial treatment of adrenal cortical cancers](#)

[Treatment of metastatic or locally advanced adrenal cortical cancer](#)

[Prognosis of adrenal cortical cancers](#)

[Adrenal medullary tumours](#)

[23 Carcinoid tumours](#)

[Presentation](#)

[Investigations](#)

[Treatment](#)

[Prognosis](#)

[24 Pituitary tumours](#)

[Epidemiology and pathology](#)

[Treatment](#)

[25 Parathyroid cancers](#)

[Epidemiology and pathology](#)

[Multiple endocrine neoplasia](#)

[Presentation and treatment](#)

[26 Lung cancer](#)

[Epidemiology](#)

Smoking and prevention

Pathogenesis

Screening

Presentation

Pathology

Staging and grading

Treatment

27 Mesothelioma

Epidemiology

Pathogenesis

Presentation

Investigations

Treatment

Prognosis

28 The leukaemias

Epidemiology

Pathogenesis

Presentation

Investigations and classification

Treatment

29 Hodgkin's lymphoma

Epidemiology

Pathogenesis

Presentation

Investigations

Pathology

Staging

Treatment and side effects

Complications of chemotherapy

30 Non-Hodgkin's lymphoma

Epidemiology

Pathogenesis

Presentation

Staging and grading

Treatment

31 Myeloma

Epidemiology

Pathogenesis

Presentation

Investigations

Treatment

32 Non-melanoma skin tumours

Epidemiology

Pathogenesis

Presentation

Treatment

Prognosis

33 Melanoma

Epidemiology

Pathogenesis

Presentation

Staging and grading

Treatment

Prognosis

34 Paediatric solid tumours

Epidemiology

Pathogenesis

Presentation and management of paediatric solid tumours

Presentation and management of CNS tumours

Presentation and management of lymphomas

Presentation and management of soft tissue sarcomas and bone tumours

Presentation and management of neuroblastoma

Presentation and management of Wilms' tumours (nephroblastoma).

Presentation and management of retinoblastoma

Presentation and management of liver tumours

Complications of childhood treatment of cancer

35 Cancers in teenagers and young adults

Epidemiology

Presentation and management of paediatric solid tumours

36 Bone and soft tissue sarcomas

Epidemiology

Pathogenesis

Presentation

Investigations and management of bone sarcomas

Treatment of Ewing's sarcomas

Treatment of osteosarcomas

Investigations and management of soft tissue sarcomas

Treatment of soft tissue sarcomas

37 Cancer of unknown primary.

Epidemiology and pathogenesis

[Clinical sites of metastatic spread](#)

[Clinical CUP syndromes](#)

[Histopathological characterization](#)

[Use of tumour markers](#)

[Approach to investigation of metastatic disease to establish primary site](#)

[38 Immunodeficiency-related cancers](#)

[Hereditary or primary immunodeficiency](#)

[Acquired or secondary immunodeficiency](#)

[Tumours in HIV patients](#)

[Tumours in primary immunodeficiency](#)

[Management of immunodeficiency-associated malignancies](#)

[Part 3 The practice of oncology](#)

[39 Paraneoplastic complications of cancer](#)

[Paraneoplastic endocrine complications](#)

[Paraneoplastic neurological conditions](#)

[Paraneoplastic dermatological conditions](#)

[Cachexia](#)

[40 Oncological emergencies](#)

[Metabolic disorders](#)

[Tumour lysis syndrome](#)

[Mechanical complications](#)

[Malignant effusions](#)

[Haematological disorders](#)

[Myelosuppression](#)

[Anaemia](#)

[Thrombocytopenia](#)

[41 End-of-life care](#)

[Pain control](#)

[Care of the dying patient](#)

[The last hours and days](#)

[Bereavement](#)

[The culture of death and dying](#)

[42 Cancer survivorship](#)

[Index](#)

[EULA](#)

List of Tables

[Chapter 1](#)

[**Table 1.1**](#)

[**Table 1.2**](#)

[**Table 1.3**](#)

[**Table 1.4**](#)

[**Table 1.5**](#)

[**Table 1.6**](#)

[**Table 1.7**](#)

[**Table 1.8**](#)

[**Table 1.9**](#)

[Chapter 2](#)

[**Table 2.1**](#)

[**Table 2.2**](#)

[**Table 2.3**](#)

[**Table 2.4**](#)

[**Table 2.5**](#)

Table 2.6

Table 2.7

Table 2.8

Table 2.9

Table 2.10

Table 2.11

Table 2.12

Table 2.13

Chapter 3

Table 3.1

Table 3.2

Table 3.3

Table 3.4

Table 3.5

Table 3.6

Table 3.7

Table 3.8

Table 3.9

Table 3.10

Table 3.11

Table 3.12

Table 3.13

Table 3.14

Table 3.15

Table 3.16

Table 3.17

Chapter 4

Table 4.1

Table 4.2

Chapter 5

Table 5.1

Table 5.2

Table 5.3

Table 5.4

Chapter 6

Table 6.1

Table 6.2

Table 6.3

Table 6.4

Table 6.5

Table 6.6

Chapter 7

Table 7.1

Table 7.2

Chapter 8

Table 8.1

Table 8.2

Chapter 9

Table 9.1

Table 9.2

Chapter 10

Table 10.1

Table 10.2

Table 10.3

Chapter 11

Table 11.1

Table 11.2

Table 11.3

Table 11.4

Chapter 12

Table 12.1

Table 12.2

Chapter 13

Table 13.1

Table 13.2

Table 13.3

Chapter 14

Table 14.1

Table 14.2

Chapter 18

Table 18.1

Table 18.2

Chapter 19

Table 19.1

Table 19.2

Chapter 20

Table 20.1

Table 20.2

Chapter 21

Table 21.1

Table 21.2

Chapter 23

Table 23.1

Chapter 24

Table 24.1

Chapter 25

Table 25.1

Chapter 26

Table 26.1

Chapter 27

Table 27.1

Table 27.2

Chapter 28

Table 28.1

Table 28.2

Table 28.3

Table 28.4

Chapter 29

Table 29.1

Chapter 30

Table 30.1

Table 30.2

Table 30.3

Table 30.4

Table 30.5

Chapter 31

Table 31.1

Table 31.2

Table 31.3

Table 31.4

Chapter 32

Table 32.1

Table 32.2

Chapter 33

Table 33.1

Table 33.2

Chapter 34

Table 34.1

Table 34.2

Table 34.3

Table 34.4

Chapter 35

Table 35.1

Chapter 36

Table 36.1

Table 36.2

Table 36.3

Table 36.4

Table 36.5

Table 36.6

Table 36.7

Chapter 37

Table 37.1

Table 37.2

Table 37.3

Table 37.4

Table 37.5

Chapter 38

Table 38.1

Chapter 39

Table 39.1

Table 39.2

Table 39.3

Table 39.4

Table 39.5

Chapter 40

Table 40.1

Table 40.2

Table 40.3

Table 40.4

Table 40.5

Chapter 41

Table 41.1

Table 41.2

Table 41.3

Chapter 42

Table 42.1

List of Illustrations

Chapter 1

Figure 1.1 Fastest changing cancer incidences in men in the United Kingdom over the last decade. NMSC, non-melanoma skin cancer.

Figure 1.2 Fastest changing cancer incidences in women in the United Kingdom over the last decade.

Figure 1.3 The Frank architecture of cancer. Normal tissue architecture is ordered, structured and controlled like a Frank Lloyd Wright building. Cancer tissues are higgledy-piggledy heaped on top of each other without any apparent planning like some of the buildings of Frank Gehry. (a) Frank Lloyd Wright designed the Guggenheim museum in New York. (b) Frank Gehry designed the Lou Ruvo centre for brain health in Las Vegas. (c) Normal retina histology. (d) Retinoblastoma histology.

Figure 1.4 Ewing's sarcoma cells with large prominent purple nuclei surrounded by a thin pink rim of cytoplasm, demonstrating the high nuclear:cytoplasmic ratio of cancer cells.

Figure 1.5 Many large dark nucleoi are seen here within the nuclei of cancer cells in this prostate adenocarcinoma.

Figure 1.6 Poorly differentiated squamous cell lung cancer with a prominent mitotic figure.

Figure 1.7 Small cell lung cancer containing several darkly stained hyperchromatic nuclei.

Figure 1.8 Preparing a histology slide. (a) Tissue is embedded in paraffin wax. (b) Thin sections of the tissue are sliced by a microtome. (c) Tissue sections are floated onto a glass slide. (d) The tissue sections on the glass slide are then stained.

Figure 1.9 (a) Normal breast duct. (b)+(c) Ductal carcinoma *in situ* (DCIS). (d) Invasive ductal cancer.

Figure 1.10 Progression of pre-invasive anal cancer with associated cytopathology changes.

Figure 1.11 Grading breast cancer.

Figure 1.12 Gene expression profiles for breast cancer samples differentiate tumours into good- and poor-prognosis signatures that predict survival.

Figure 1.13 Immunocytochemical staining in breast cancer.

Figure 1.14 (a) Lymphatic invasion and (b) perineural invasion.

Figure 1.15 Global incidences for prostate, breast, stomach and cervical cancers. Darker colours denote higher incidence.

Chapter 2

Figure 2.1 Signal transduction pathway.

Figure 2.2 Oscillating levels of cyclins through the phases of the cell cycle.

Figure 2.3 The cell cycle.

Figure 2.4 The apoptotic pathway.

Figure 2.5 Telomerase, telomere length, senescence and immortalization.

Figure 2.6 The angiogenic switch.

Figure 2.7 Cell-cell and cell-matrix interactions.

Figure (a) Lung metastases. Plain chest radiograph showing multiple rounded metastases of varying sizes in a man with a metastatic testicular non-seminomatous germ cell tumour. Other tumours that commonly metastasize to the lungs include lung, breast, renal and thyroid cancers and sarcomas. (b) Bone metastases. Mixed sclerotic and lucent bone metastases of prostate cancer. (c) Ultrasound images of liver metastases. (d) CT images of liver metastases. (e) Patient with multiple cutaneous metastases from non-small cell lung cancer. (f) Sub-diaphragmatic peritoneal deposit and extensive ascites. The patient had advanced ovarian cancer and the peritoneal deposits have travelled from the primary site in the ascitic fluid. This is known as transcoelomic spread or spread across a body cavity (from “koilōma”, the Greek word for a hollow or cavity).

Figure 2.8 Stepwise accumulation of genetic mutations contributing to oncogenic phenotype.

Figure 2.9 Colon cancer development from normal mucosa to metastatic carcinoma associated with stepwise acquisition of oncogenic mutations. APC, adenomatous polyposis coli gene; KRAS, Kirsten rat sarcoma viral oncogene homologue; p53, tumour

protein 53 (TP53); SMAD, *Homo sapiens* homologue of *Drosophila* protein mothers against decapentaplegic (MAD); VEGF, vascular endothelial growth factor.

Figure 2.10 DNA methylation is passed on during cell replication to progeny cells by DNA methyltransferase enzymes that methylate CpG islands. CpG refers to the DNA dinucleotide sequence CG joined by the phosphate backbone of DNA.

Figure 2.11 Mechanism of chromatin modification. Ac, acetyl; HAT, histone acetyltransferase; HDAC, histone deacetylase; HMT, histone methyltransferase; Me, methyl.

Figure 2.12 Mechanism of RNA interference.

Figure 2.13 Proteasome pathway of protein ubiquitination and degradation. E, ubiquitination enzymes; Ub, ubiquitin.

Figure 2.14 Knudson's two-hit hypotheses of familial and sporadic retinoblastoma.

Figure 2.15 Multiple dermal neurofibromata typical of peripheral neurofibromatosis or type 1 NF, previously known eponymously as von Recklinghausen's disease. It is due to hereditary mutation of the NF1 neurofibromin gene on chromosome 2p22, which encodes a guanosine triphosphatase (GTPase) activating protein involved in the signal transduction cascade.

Figure 2.16 The maths of cancer.

Figure 2.17 UV-light-induced thymidine dimers. T, Thymine; A, Adenine.

Figure 2.18 How atomic bombs kill.

Figure 2.19 Osteosarcoma of the first metacarpal 15 years after radiotherapy for arthritis (no longer used). This radiograph shows cortical destruction, a soft tissue mass with internal calcification and periosteal reaction.

Figure 2.20 The onco tree of life. HPV, Human Papillomavirus; EBV, Epstein Barr virus; KSHV, Kaposi sarcoma herpesvirus; HBV, Hepatitis B virus; HCV, Hepatitis C virus; MCV, Merkel cell polyoma virus; HTLV, Human T cell leukemia virus.

Figure 2.21 KSHV-related tumours. Immunohistochemistry staining for KSHV latent nuclear antigen (LANA) shows the presence of virus in spindle cells of Kaposi's sarcoma and the plasmablasts in multicentric Castleman's disease. KSHV, Kaposi's sarcoma herpesvirus (also known as Human herpesvirus (HHV8)).

Chapter 3

Figure 3.1 T-stage classification for bladder cancer and influence on survival. CIS, carcinoma *in situ*; Ta, non-invasive papillary tumour; T1, tumour invades subepithelial connective tissue; T2, tumour invades superficial muscle; T3, tumour invades deep muscle or perivesical fat; T4, tumour invades prostate, uterus, vagina, pelvic wall or abdominal wall.

Figure 3.2 T1 (left) and T2 (right) MRI scans demonstrating a large right basal ganglia glioma with midline shift, compression of the right lateral ventricle and peritumoural oedema.

Figure 3.3 (a) T2-MRI and FDG-PET scan showing an FDG avid parietal primary cerebral lymphoma. (b) CT and FDG-PET scans demonstrating a huge right axillary and anterior chest wall mass due to Burkitt

lymphoma. The FDG-PET also demonstrates extensive involvement of other nodal groups, bones and the right kidney upper pole (stage 4B). FDG, Fluorodeoxyglucose; PET, positron emission tomography.

Figure 3.4 Plain pelvic radiograph (above) and corresponding area of technetium pyrophosphate bone scan (below) of a patient with sclerotic bone metastases from prostate cancer.

Figure 3.5 Oesophageal stent to palliate dysphagia.

Figure 3.6 Pathological spiral fracture through right femoral shaft metastasis from prostate cancer repaired with a distal femoral plate.

Figure 3.7 How radiation damages DNA.

Figure 3.8 A brief lesson in particle physics.

Figure 3.9 (a) Squamous cell cancer of the oral cavity. (b) Radiological verification of the radiotherapy fields. (c) The planned radiotherapy fields.

Figure 3.10 Comparison of conventional and intensity-modulated radiotherapy planning.

Figure 3.11 Prostate brachytherapy seeds *in situ* seen on pelvic X-ray.

Figure 3.12 Selective internal radiation therapy (SIRT) using microspheres loaded with radioisotopes (in this case Yttrium-90) injected into the hepatic arteries to treat inoperable liver cancer. The microspheres are about one-third the size of a human hair width.

Figure 3.13 Clearly demarcated scalp alopecia due to radiotherapy.